J.P. Morgan analyst Chris Schott maintained a Hold rating on Johnson & Johnson yesterday and set a price target of $185.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Chris Schott has given his Hold rating due to a combination of factors influencing Johnson & Johnson’s performance. The company has shown strong results in its recent quarterly earnings, with both its Innovative Medicines and MedTech segments exceeding expectations. This positive performance has led to an increase in sales guidance, driven by favorable foreign exchange rates and core business strength. However, despite these positive developments, Schott maintains a Hold rating due to ongoing challenges that the company faces.
One of the primary concerns is the impact of biosimilar competition on J&J’s largest drug, Stelara, which is expected to experience significant sales erosion. Additionally, while the company is making progress in addressing the talc litigation overhang, it remains a significant risk factor. These issues, alongside the company’s current valuation, contribute to Schott’s decision to maintain a neutral stance on the stock, despite the company’s potential for sustained growth in its core segments.
In another report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $165.00 price target.